IL149701A0 - Use of anti-ctla-4 antibodies - Google Patents
Use of anti-ctla-4 antibodiesInfo
- Publication number
- IL149701A0 IL149701A0 IL14970102A IL14970102A IL149701A0 IL 149701 A0 IL149701 A0 IL 149701A0 IL 14970102 A IL14970102 A IL 14970102A IL 14970102 A IL14970102 A IL 14970102A IL 149701 A0 IL149701 A0 IL 149701A0
- Authority
- IL
- Israel
- Prior art keywords
- ctla
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29304201P | 2001-05-23 | 2001-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL149701A0 true IL149701A0 (en) | 2002-11-10 |
Family
ID=23127385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14970102A IL149701A0 (en) | 2001-05-23 | 2002-05-16 | Use of anti-ctla-4 antibodies |
Country Status (14)
Country | Link |
---|---|
US (1) | US20030086930A1 (ja) |
EP (1) | EP1262193A1 (ja) |
JP (1) | JP2002371013A (ja) |
KR (1) | KR100531707B1 (ja) |
CN (1) | CN1404876A (ja) |
AU (1) | AU4242102A (ja) |
CA (1) | CA2382443A1 (ja) |
CZ (1) | CZ20021760A3 (ja) |
HU (1) | HUP0201737A2 (ja) |
IL (1) | IL149701A0 (ja) |
MY (1) | MY136095A (ja) |
PL (1) | PL354112A1 (ja) |
SK (1) | SK7242002A3 (ja) |
ZA (1) | ZA200204020B (ja) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US7357928B2 (en) * | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
AU2003234736B2 (en) * | 2002-04-12 | 2008-09-25 | E. R. Squibb & Sons, L.L.C. | Methods of treatment using CTLA-4 antibodies |
BRPI0314038B8 (pt) | 2002-09-06 | 2021-05-25 | Amgen Inc | anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica |
US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
AU2004260936B2 (en) | 2003-06-27 | 2010-06-10 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
RU2377252C2 (ru) * | 2003-07-22 | 2009-12-27 | Шеринг Акциенгезельшафт | Rg1 антитела и их применение |
CA2535859A1 (en) * | 2003-08-14 | 2005-03-03 | Dyax Corp. | Endotheliase-2 ligands |
EP1515505A1 (en) * | 2003-09-12 | 2005-03-16 | Siemens Aktiengesellschaft | Reachability maintainance of a moving network based on temporary name identifiers |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
JP2007526455A (ja) * | 2004-02-03 | 2007-09-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法 |
CA2560919A1 (en) * | 2004-03-26 | 2005-10-06 | Pfizer Products Inc. | Uses of anti-ctla-4 antibodies |
US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
JP2008518902A (ja) * | 2004-11-04 | 2008-06-05 | ファイザー・プロダクツ・インク | 乳癌のためのctla4抗体とアロマターゼ阻害剤の併用治療 |
NZ560844A (en) | 2005-03-08 | 2008-08-29 | Pharmacia & Upjohn Co Llc | Anti-MAdCAM antibody compositions |
KR20070108259A (ko) * | 2005-03-23 | 2007-11-08 | 화이자 프로덕츠 인크. | Ctla-4 항체와 호르몬 요법에 의한 전립선암의 치료법 |
EP1863532A1 (en) * | 2005-03-23 | 2007-12-12 | Pfizer Products Incorporated | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
NZ563193A (en) * | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
US8652465B2 (en) | 2005-06-08 | 2014-02-18 | Emory University | Methods and compositions for the treatment of persistent infections |
NZ565311A (en) * | 2005-07-07 | 2009-10-30 | Pfizer | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
WO2007067959A2 (en) | 2005-12-07 | 2007-06-14 | Medarex, Inc. | Ctla-4 antibody dosage escalation regimens |
EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
WO2009016449A1 (en) * | 2007-07-27 | 2009-02-05 | Pfizer Limited | Antibody purification process by precipitation |
NZ584848A (en) | 2007-09-28 | 2012-09-28 | Intrexon Corp | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
CN101909693A (zh) * | 2008-01-08 | 2010-12-08 | 百时美施贵宝公司 | 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合 |
US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
SI2769737T1 (sl) * | 2009-07-20 | 2017-06-30 | Bristol-Myers Squibb Company | Kombinacija anti-ctla4 protitelesa z etoposidom za sinergistično zdravljenje proliferativnih bolezni |
US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
PL3446714T3 (pl) | 2011-06-02 | 2021-11-22 | University Of Louisville Research Foundation, Inc. | Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie |
SI2825558T1 (sl) | 2012-03-13 | 2019-08-30 | F. Hoffmann-La Roche Ag | Kombinirana terapija za zdravljenje raka jajčnikov |
PE20142406A1 (es) | 2012-05-04 | 2015-01-23 | Pfizer | Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna |
US8968742B2 (en) * | 2012-08-23 | 2015-03-03 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins |
CN104968364A (zh) * | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
EP3030262B1 (en) | 2013-08-08 | 2019-10-09 | Cytune Pharma | Combined pharmaceutical composition |
MX2016001555A (es) | 2013-08-08 | 2016-08-03 | Cytune Pharma | Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra). |
WO2015058048A1 (en) * | 2013-10-18 | 2015-04-23 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
MX2016012891A (es) * | 2014-03-31 | 2017-10-12 | Univ Johns Hopkins | Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido. |
KR20170002403A (ko) * | 2014-05-01 | 2017-01-06 | 가부시키가이샤 아네로파마·사이엔스 | 이종 폴리펩티드 발현 카세트 |
EA201692458A1 (ru) | 2014-05-28 | 2017-06-30 | Агенус Инк. | Анти-gitr антитела и способы их применения |
CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
HUE043847T2 (hu) | 2014-08-28 | 2019-09-30 | Halozyme Inc | Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
DK3207130T3 (da) | 2014-10-14 | 2019-11-11 | Halozyme Inc | Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme |
AU2015374385B2 (en) | 2014-12-31 | 2020-08-06 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
JP6917902B2 (ja) * | 2015-02-13 | 2021-08-11 | ソレント・セラピューティクス・インコーポレイテッド | Ctla4に結合する抗体医薬 |
EP3291839A1 (en) | 2015-05-05 | 2018-03-14 | The University of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
BR112017025564B8 (pt) * | 2015-05-29 | 2022-01-04 | Agenus Inc | Anticorpos anti-ctla-4 e métodos de uso dos mesmos |
CN108348601B (zh) * | 2015-07-22 | 2022-05-17 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
MA44483A (fr) | 2016-03-24 | 2019-01-30 | Millennium Pharm Inc | Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires |
EP3436066A1 (en) | 2016-04-01 | 2019-02-06 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
EA039322B1 (ru) * | 2016-04-15 | 2022-01-13 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
CN109906088A (zh) * | 2016-08-26 | 2019-06-18 | 奥野哲治 | 微血管血流减少剂及其应用 |
KR20230037664A (ko) * | 2016-12-07 | 2023-03-16 | 아게누스 인코포레이티드 | 항-ctla-4 항체 및 이의 사용 방법 |
MA50948A (fr) | 2016-12-07 | 2020-10-14 | Agenus Inc | Anticorps et procédés d'utilisation de ceux-ci |
CN111699195A (zh) * | 2018-02-02 | 2020-09-22 | 肿瘤免疫股份有限公司 | 具有改善的免疫治疗效果但减轻的不良作用的突变体抗ctla-4抗体 |
US20210040212A1 (en) * | 2018-02-02 | 2021-02-11 | Oncolmmune, Inc. | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
EP3768721A4 (en) * | 2018-03-19 | 2021-12-29 | Wuxi Biologics Ireland Limited. | Novel anti-ctla-4 antibody polypeptide |
AU2019251421A1 (en) | 2018-04-09 | 2020-10-29 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
CN110092826B (zh) * | 2019-02-28 | 2022-04-15 | 天津大学 | CTLA-4类似物CFN13及CFN13-Fc基因和蛋白 |
CN115803343A (zh) * | 2020-05-26 | 2023-03-14 | 百奥泰生物制药股份有限公司 | 多特异性抗体及其应用 |
WO2022010537A1 (en) | 2020-07-10 | 2022-01-13 | The Regents Of The University Of Michigan | Gas41 inhibitors and methods of use thereof |
EP4343004A3 (en) | 2020-10-19 | 2024-09-11 | Dana-Farber Cancer Institute, Inc. | Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
EP4326321A1 (en) | 2021-04-20 | 2024-02-28 | Institut Curie | Compositions and methods for use in immunotherapy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994362A (en) * | 1992-03-11 | 1999-11-30 | Merck & Co., Inc. | Method of treatment for prostatic cancer |
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
PT2112166T (pt) * | 1998-12-23 | 2019-01-30 | Pfizer | Anticorpos monoclonais humanos contra ctla-4 |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
KR100942863B1 (ko) * | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
US7183376B2 (en) * | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
-
2002
- 2002-05-16 IL IL14970102A patent/IL149701A0/xx unknown
- 2002-05-17 JP JP2002142978A patent/JP2002371013A/ja active Pending
- 2002-05-17 CA CA002382443A patent/CA2382443A1/en not_active Abandoned
- 2002-05-21 CZ CZ20021760A patent/CZ20021760A3/cs unknown
- 2002-05-21 AU AU42421/02A patent/AU4242102A/en not_active Abandoned
- 2002-05-21 ZA ZA200204020A patent/ZA200204020B/xx unknown
- 2002-05-22 US US10/153,382 patent/US20030086930A1/en not_active Abandoned
- 2002-05-22 KR KR10-2002-0028317A patent/KR100531707B1/ko not_active IP Right Cessation
- 2002-05-22 MY MYPI20021892A patent/MY136095A/en unknown
- 2002-05-23 PL PL02354112A patent/PL354112A1/xx not_active Application Discontinuation
- 2002-05-23 SK SK724-2002A patent/SK7242002A3/sk not_active Application Discontinuation
- 2002-05-23 HU HU0201737A patent/HUP0201737A2/hu unknown
- 2002-05-23 EP EP02253652A patent/EP1262193A1/en not_active Withdrawn
- 2002-05-23 CN CN02120349A patent/CN1404876A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA200204020B (en) | 2003-11-21 |
CZ20021760A3 (cs) | 2003-05-14 |
KR100531707B1 (ko) | 2005-11-30 |
HUP0201737A2 (hu) | 2003-02-28 |
SK7242002A3 (en) | 2003-07-01 |
EP1262193A1 (en) | 2002-12-04 |
AU4242102A (en) | 2002-11-28 |
CA2382443A1 (en) | 2002-11-23 |
KR20020090873A (ko) | 2002-12-05 |
CN1404876A (zh) | 2003-03-26 |
JP2002371013A (ja) | 2002-12-26 |
HU0201737D0 (ja) | 2002-07-29 |
PL354112A1 (en) | 2002-12-02 |
US20030086930A1 (en) | 2003-05-08 |
MY136095A (en) | 2008-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL149701A0 (en) | Use of anti-ctla-4 antibodies | |
IL158831A0 (en) | METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES | |
EP1432444A4 (en) | ANTI-BETA ANTIBODIES | |
HK1074206A1 (en) | Anti-trail-r antibodies | |
IL160373A0 (en) | Antagonistic anti-htnfsf13b human antibodies | |
HUP0402164A3 (en) | Polycistronic expression of antibodies | |
IL157142A0 (en) | Modified antibodies and methods of use | |
IL158643A (en) | Anti-hmg monoclonal antibodies and compositions containing the same | |
EP1391464A4 (en) | ANTI-CD40 MONOCLONAL ANTIBODY | |
IL175935A0 (en) | Solid forms of anti-egfr antibodies | |
SI1587542T1 (sl) | Uporaba anti-cd100 protiteles | |
AU2002340167A8 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
AU2002365649A8 (en) | Anti-dota antibody | |
GB0126378D0 (en) | Antigen | |
EP1393746A4 (en) | COMPOSITIONS WITH THE HUMAN POLYCLONAL ANTIBODY | |
AU2002242447A1 (en) | Use of polyclonal immunoglobulins | |
EP1446416A4 (en) | TUMOR-SPECIFIC MONOCLONAL ANTIBODIES | |
ZA200508071B (en) | Polycistronic expression of antibodies | |
GB0119553D0 (en) | Antibodies | |
GB0121727D0 (en) | Monoclonal antibodies | |
GB0118696D0 (en) | Novel antibodies | |
GB0119004D0 (en) | Antibody | |
AU2002211364A1 (en) | Human anti-cd40 antibodies | |
GB0126522D0 (en) | Antigen | |
GB0016824D0 (en) | Human monoclonal antibodies |